Pharma Partnering EU

Biocom is excited to announce the upcoming Noven Pharmaceuticals Partner Day on Wednesday, June 10. To explore potential collaboration opportunities through 1:1 meetings with Noven Pharmaceuticals leadership, please submit an application by Monday, May 25.Representatives from Noven Pharmaceuticals will be in attendance and are interested in 1:1 meetings with companies fitting the criteria below. They welcome opportunities that enhance or support their pipeline of products to address unmet medical needs in serious disease areas. Objectives include asset licensing, external research agreements and regionally focused partnerships.About Noven Pharmaceuticals: Noven Pharmaceuticals, the U.S. subsidiary of Hisamitsu Pharmaceutical, is a dynamic specialty pharmaceutical company engaged in the research, development, manufacture, marketing, and sale of prescription pharmaceutical products. We are committed to developing and offering pharmaceutical products that meaningfully benefit patients, with a commitment to advancing patient care through transdermal drug delivery.Areas of Interest1. Transdermal Drug Delivery (TDDS) – API OpportunitiesWe are interested in active pharmaceutical ingredients (APIs) suitable for transdermal drug delivery using proprietary TDDS technologies.1.1 Platform TechnologiesDOT-Matrix TechnologyDrug is solubilized at high concentrations, enabling highly efficient transdermal deliveryGel Patch TechnologyProvides superior elasticity for application to joints (e.g., knees, elbows), improving comfort and reducing skin irritation(This technology is also used in widely recognized OTC patch products such as Salonpas)1.2 Dosage FormsPatch-based systemsOther topical formulations (e.g., creams, gels, lotions)Microneedle-based system1.3 Target Indications (Key Focus)Broad applicability across therapeutic areasStrong preference for indications where transdermal delivery provides a clear clinical or patient compliance advantageParticularly relevant for:Patients with dysphagia or GI limitationsPediatric and elderly populationsChronic conditions requiring sustained exposure1.4 Target Modalities (Key Focus)Small moleculesPeptidesNucleotidesPreference for modalities compatible with controlled, sustained transdermal absorption profilesVaccine (Microneedle)1.5 Development StagePrograms with identified lead compounds or beyondEstablished mechanism of action (MoA) or clinical validation in related indications1.6 Potential Benefits of TDDSImproved ease of administration for pediatric, elderly, or dysphagic patientsSustained systemic exposure may reduce systemic and GI adverse eventsImproved bioavailability for drugs with significant first-pass metabolism2. Therapeutic Area–Focused AssetsWe seek differentiated assets across priority therapeutic areas.2.1 Therapeutic Areas of InterestWomen’s HealthNeurology (including narcolepsy, ALS, Alzheimer’s disease, myasthenia gravis, sleep disorders, Parkinson’s disease, epilepsy)PsychiatryDermatologyOrthopedics / Muscle-related diseasePainRare diseases2.2 Target Modalities & Dosage Forms (Key Focus)All modalities excluding gene therapy and cell therapyAll dosage forms are acceptable not limited to transdermal deliveryPreference for assets with clear differentiation in delivery, efficacy, or safety profile2.3 Development StageAssets beyond discovery stagePreference for programs with demonstrated proof of concept (POC)2.4 Evaluation CriteriaStrong translational rationale linking MoA to human efficacyAvailability of in vivo or animal POC data supporting the target product profile3. Next-Generation TDDS & Drug Delivery TechnologiesWe are interested in enabling technologies that advance transdermal and alternative delivery systems.3.1 Transdermal Absorption EnhancementMaterials or technologies that improve permeation across biological barriers (e.g., stratum corneum)Minimally invasive transdermal delivery systems and devices3.2 Film-Based Drug Delivery (Oral, Sublingual, Vaginal)Technologies enabling higher drug loading in thin filmsInnovations that enhance dissolution and release of active compounds3.3 Monitoring & Digital Health IntegrationWearable or device-based technologiesCapability to monitor drug levels or biomarkers (e.g., hormones) in real timePlease ensure you are providing accurate and specific answers in this application to ensure the best fit with the appropriate group at Noven Pharmaceuticals. Application Deadline: May 25.<< APPLY HERE >>Important Details:ONLY COMPLETED APPLICATIONS WILL BE ACCEPTEDThis event is scheduled for Wednesday June 10, from 9 a.m. – 3 p.m. PDT and will take place in San Diego.Selected companies must be available to attend in person.Selected applicants will be notified directly no later than Friday, May 31.Please note that registering for the event does not guarantee a meeting with the Noven Pharmaceutical teams; you must submit an application. Selected companies will be notified directly.